Slides:

Advertisements

Similar presentations

 Incidence rate (symptomatic): 1%  ½ occur after discharge  We don’t understand which patients are at highest risk.

Advertisements

The EINSTEIN DVT Study 'Xarelto' for the Acute and Continued Treatment of Symptomatic Deep Vein Thrombosis.

DEFINING THE DURATION OF ANTICOAGULATION. HOW LONG TO TREAT A DVT?

Preventing Hospital Acquired Thrombosis Simon Noble Peggy Edwards.

Complicanze trombotiche nel mieloma multiplo Mauro Berrettini S.C. Medicina Generale-DH Oncologico Ospedale di Orvieto Mediterranean School of Oncology.

Pulmonary Embolism Treatment in Cancer - Is It Different 34th Brazilian Thoracic Conference 6th ALAT Congress 5th Brazil-Portugal Congress Brazilia/DF.

Warfarin Efficacy in Cancer Patients on Long-term Anticoagulation Neha Doshi, PharmD Candidate LeAnn B. Norris, PharmD, BCPS P. Brandon Bookstaver, PharmD,

Chapter Seven Venous Disease Coalition Long-Term Management of VTE VTE Toolkit.

Risk assessment for VTE Dr Roopen Arya King’s College Hospital.

Higher Incidence of Venous Thromboembolism (VTE) in the Outpatient versus Inpatient Setting Among Patients with Cancer in the United States Khorana A et.

Dabigatran Etexilate is Effective and Safe for the Extended Prevention of Venous Thromboembolism Following Total Hip Replacement Eriksson BI, Dahl OE,

SANOFI-SYNTHELABOARIXTRA ® 1 ARIXTRA ® (fondaparinux sodium) in the prevention of venous thromboembolism after hip replacement surgery KA Bauer, BI Eriksson,

Breast cancer affects 1 in 8 women during their lives. 1 Population Statistics.

Educational Purposes. Coalition To Prevent VTE - Risk Assessment.

Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study by Cheng E. Chee, Aneel A. Ashrani,

Venous Thromboembolic (VTE) Prophylaxis in Pediatric Trauma Patients Bowe.

Conclusions Results Methods Background Venous thrombo-embolism in patients undergoing neo- adjuvant chemotherapy and surgery for oesophago-gastric cancer.

Chapter 9: Vascular Complications of Cancer and Cancer Treatment

Taylor Butler, PharmD, BCOP Decentralized Clinical Pharmacist

Thrombosis.TV Breaking Update: Betrixaban Approved by the FDA

The VERITY Steering Committee

Clinical Professor in Palliative Medicine

Clinical evaluation of UHC for cancer

UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER

APEX Trial design: Patients hospitalized with an acute medical illness were randomized to oral betrixaban for days (n = 3,759) versus subcutaneous.

D-dimer and helical CT-PA based diagnostic algorithm for PE

Dr.H.Chandrashekar, Dr.A.Chaudhuri, Dr. A. Douglas, Dr. D. Lowdon

UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER

Waleed Alselwi1, Thomas Coventary2, Faisal Azam1

Shortened Coagulation profile in Pregnancy - A Comparative analysis in different trimesters: Retrospective study from a tertiary care centre Bhavika Rishi,

NOACs for Cancer-Associated Thrombosis:

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,

Timothy A. Brighton, M. B. , B. S. , John W. Eikelboom, M. B. , B. S

The Burden of Hospital-Associated Venous Thromboembolism

Overall burden of AF associated with higher risk of thromboembolism and ischemic stroke An analysis of the KP-RHYTHM study, in patients with paroxysmal.

Incidence, risk factors, and treatment patterns for deep venous thrombosis in hospitalized children: An increasing population at risk John A. Sandoval,

Paul D. Stein, MD, Russell D. Hull, MBBS, MSc, Fadi Matta, MD, Abdo Y

Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism by Sabine Eichinger, Verena Schönauer, Ansgar Weltermann,

Venous Thromboembolism with Chronic Liver Disease

Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer

Incidence and Predictors Of Venous Thromboembolism Among Lymphoma Patients In Denmark: A Nationwide Population-Based Cohort Study by Jennifer L Lund, Lene.

Don't look now! Risk stratify first

Deep venous thrombosis after repair of nonruptured abdominal aneurysm

Hydroxychloroquine & Lupus

Symptomatic perioperative venous thromboembolism is a frequent complication in patients with a history of deep vein thrombosis Timothy K. Liem, MD, Thanh.

References: What is the connection between VTE and active cancer? 1. Khorana AA, Francis CW, Culakova E et al. Thromboembolism.

References: Oncological Surgyery: 1. ASCO: Lyman GH, Bohlke K, Khorana AA, et al. Venous Thromboembolism Prophylaxis and Treatment.

How I treat cancer-associated venous thromboembolism

Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.

Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.

References: Anticoagulation should be continued 3-6 months for the treatment of VTE in cancer patients: 1. ASCO: Lyman GH, Bohlke K, Khorana AA, et al.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Disease Burden of VTE Phases of VTE Treatment.

Venous thromboembolism in chronic lymphocytic leukemia: a Danish nationwide cohort study by Inger Lise Gade, Signe Juul Riddersholm, Ilse Christiansen,

Prevention of hospital-acquired thrombosis from a primary care perspective: a qualitative study by Ian Litchfield, David Fitzmaurice, Patricia Apenteng,

by Paul Baughan, Jennifer Keatings, and Bill O'Neill

3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).

Overall burden of AF associated with higher risk of thromboembolism and ischemic stroke An analysis of the KP-RHYTHM study, in patients with paroxysmal.

Incidence, risk factors, and treatment patterns for deep venous thrombosis in hospitalized children: An increasing population at risk John A. Sandoval,

Comparison of end-of-life care for older people living at home and in residential homes: a mortality follow-back study among GPs in the Netherlands by.

Two run charts showing the effects of Plan, Do, Study, Act cycles on 24-hour Electronic Patient Records venous thromboembolism (EPR VTE) risk assessment.

A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.

Increased frequency and number of KLL-specific clonotypes in tumors is associated with improved MCC-specific survival. Increased frequency and number of.

Cumulative prevalence of venous thromboembolic events in ITP patients who underwent splenectomy compared with those who did not. Cumulative prevalence.

Deep venous thrombosis after repair of nonruptured abdominal aneurysm

Presentation transcript:

References: Thanks to improved treatment strategies, patients with cancer are surviving longer and undergoing more cancer treatments. In the future, this will increase the incidence of VTE for cancer patients: 1. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013 Sep 5;122(10):1712-23. 2. Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 2011;117:1334–1349. 3. Cronin-Fenton DP, Søndergaard F, Pedersen LA, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006. British journal of cancer. 2010 Sep;103(7):947. 4. Stein PD, Beemath A, Meyers FA, et al. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006 Jan;119(1):60-8. 5. Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. Thrombosis and haemostasis. 2017 Jan;117(01):57-65. Risk of VTE is higher in the first 3 months of cancer after diagnosis: 1. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013 Sep 5;122(10):1712-23 2. Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 2011;117:1334-1349. VTE risk is 20 times higher for distant metastatic disease compared to localised cancer: 1. Fuentes HE, Tafur AJ, Caprini JA. Cancer-associated thrombosis. Dis Mon 2016;62(5):121-58. 2. Cronin-Fenton DP, Søndergaard F, Pedersen LA, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006. British journal of cancer. 2010 Sep;103(7):947. VTE incidence by cancer type: 1. Stein PD, Beemath A, Meyers FA, et al. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006 Jan;119(1):60-8 Incidence of a first venous thromboembolic event was highest in the elderly population: 1. Cohen AT, Katholing A, Rietbrock S, et al. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. Thrombosis and haemostasis. 2017 Jan;117(01):57-65.